Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Contact the Supplier

Lead Product(s): BI 456906

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BI 456906

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Zealand Pharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2021

Details:

The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.